Prelude Therapeutics Inc
Close on Oct 19, 2026
- Market cap
- $333.54M
- P/E (TTM)
- –
- Dividend yield
- –
About Prelude Therapeutics
Pharmaceutical Preparations, SIC 2834
Prelude Therapeutics Incorporated is a clinical-stage precision oncology biopharmaceutical company focused on discovering and developing targeted cancer therapies. The company identifies compelling biological target mechanisms, such as transcriptional regulation and cell proliferation signaling pathways, to design new chemical entities. Its product candidate pipeline utilizes multiple therapeutic modalities, including small-molecule inhibitors, targeted protein degraders, and precision antibody-drug conjugates. Prelude focuses its development programs on underserved patient populations with solid tumors and hematological malignancies that have high unmet medical needs. Key programs include lead candidates such as PRT12396, a selective JAK2 inhibitor, and preclinical candidates targeting KAT6A as well as mutated calreticulin.
The company operates primarily in the United States and conducts its research and clinical development activities domestically. Prelude conducts corporate operations from its principal executive offices and headquarters located in Wilmington, Delaware. It also collaborates with external biopharmaceutical partners to discover, develop, and commercialize novel degrader antibody conjugate programs.
Summary of the business section of Prelude Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Prelude Therapeutics Inc
- Founded
- 2016
- Headquarters
- Wilmington, DE
- Address
- 175 Innovation Boulevard 19805
- Phone
- (302) 467-1280
- Employees
- 79, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- PRLD
- Exchange
- Nasdaq
- IPO date
- Sep 25, 2020
- Shares outstanding
- 80M, Aug 6, 2026
- Public float
- $14.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1678660
- CUSIP
- 74065P101
- ISIN
- US74065P1012
- EIN
- 81-1384762
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Krishna Vaddi | CEO, Director | 2,693,623 |
| Charles Q. Morris | Chief Medical Officer | – |
| Sean P. Brusky | Chief Business Officer | 100,000 |
| Peggy Scherle | Chief Scientific Officer | 173,527 |
| Bryant David Lim | CLO, CFO, Corp Sec. | 27,400 |
| Andrew Combs | Chief Chemistry Officer | 480,123 |
| Jane Huang | President, CMO | 86,917 |
| Victor Sandor | Director | – |
| Katina Dorton | Director | – |
| Paul A. Friedman | Director | 347,522 |
| 667, L.P. | Director | – |
| Bros. Advisors Lp Baker | Director | 876,061 |
| Julian Baker | Director | – |
| Felix Baker | Director | – |
| Brothers Life Sciences LP Baker | Director | – |
| Bros. Advisors (GP) LLC Baker | Director | 870,873 |
| David P. Bonita | Director | 1,126,126 |
| Martin Babler | Director | – |
| Advisors Llc Orbimed | Director | 9,250,191 |
| Capital GP VI LLC OrbiMed | Director | – |
| Capital Llc Orbimed | Director | 10,119,756 |
| Genesis GP LLC OrbiMed | Director | 1,126,126 |
| Paul C. Scherer | Director | – |
| Mardi Dier | Director | 10,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Krishna Vaddi | $1.35M | $2.42M | $833.56K | $68 | – |
| FY2024 Krishna Vaddi | $2.33M | $448.04K | $1.32M | $30 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 79 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 28, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 25, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 16, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |